BCAL Diagnostics Limited ( (AU:BDX) ) has shared an update.
BCAL Diagnostics Limited has launched its first-in-class blood test, BREASTEST plus, which achieved its first revenues in March 2025. This launch represents a significant milestone in breast cancer diagnostics, particularly for women with dense breasts where traditional imaging is less effective. The company is expanding its market access and clinician engagement strategies in Australia, with plans for a national rollout, while also laying the groundwork for US market entry. BCAL continues to strengthen its patent portfolio and maintain a solid financial position with a cash balance of $5 million, focusing on efficient resource deployment to achieve its strategic objectives.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is a biotechnology company based in Australia and the US, specializing in non-invasive breast cancer diagnostics. The company focuses on pioneering blood tests for breast cancer detection, aiming to transform the diagnostic landscape with innovative solutions.
YTD Price Performance: -13.40%
Average Trading Volume: 308,466
Technical Sentiment Signal: Buy
Current Market Cap: A$30.74M
See more insights into BDX stock on TipRanks’ Stock Analysis page.